CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)

CIBRA Capital disclosed a purchase of 1,476,861 Amicus Therapeutics shares in its April 24, 2026 SEC filing, an estimated $21.17 million trade that lifted the position to 1,687,661 shares valued at $24.40 million. The stake now represents 11.78% of reportable AUM, making it the fund’s top holding, and the article frames the buy as merger-arbitrage exposure ahead of BioMarin’s proposed $14.50 per share acquisition. The filing is notable for position sizing and M&A context, but it is unlikely to materially affect the broader market.

Analysis

This looks less like a generic biotech endorsement and more like a high-conviction event-driven bet on deal completion. The important second-order signal is not the size of the add, but the concentration: a single-name position at nearly 12% of reportable AUM implies the manager is expressing confidence in spread capture and is willing to accept idiosyncratic deal risk over the next 1-3 months. That makes the stock behave more like a binary arb than a fundamental biotech—implied volatility should stay anchored to closing probability, not pipeline headlines.

The market’s main blind spot is that a “near-cash” price does not eliminate downside; it simply caps upside. If the transaction slips, repricing can be abrupt because the buyer base is dominated by merger-arb funds that will de-risk simultaneously, and the stock no longer has natural long-only sponsorship at these levels. In that scenario, the key question is whether the share price falls back to standalone biotechnology valuation or to a discount reflecting broken-deal odds; given the company’s negative earnings and reliance on a small number of products, the latter is the more dangerous path.

From a cross-asset perspective, the clearest beneficiary is BMRN, but the real trade is not directional biotech beta—it’s a short-dated spread trade around deal certainty. If the offer is indeed cash and regulatory risk is minimal, the remaining edge is in financing/closing timing rather than price direction, so theta is the enemy and a simple stock long has poor convexity. The contrarian angle is that the market may be overestimating how “free” this spread is; even modest delay pushes annualized return on the arb down sharply, which is why the position sizing at CIBRA reads as a timing conviction call rather than a pure arbitrage sleeve.

Key Decisions for Investors

• Long FOLD / short a biotech basket (XBI or IBB) for 1-3 months to isolate deal-spread capture; target low single-digit upside if closing stays on track, with materially larger downside if the deal timeline slips.
• If you want cleaner event risk, buy FOLD only after a post-rumor consolidation or on a spread widening move; avoid paying up at the top of the arb range where annualized carry collapses.
• Use BMRN as the cleaner relative winner: express the view via long BMRN vs short XBI into closing, because BMRN should retain more value if the deal completes while broader biotech beta remains noisy.
• Avoid selling naked calls on FOLD unless you can tolerate gap risk; a broken-deal headline could reprice the name 15-30% lower quickly, overwhelming premium collected.
• Set a hard catalyst watch over the next 30-60 days: any regulatory or financing delay should trigger immediate de-risking, since the spread is only attractive while time-to-close remains short.